These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38523924)
1. Effective Treatment of Lung Adenocarcinoma With a Novel SLC44A1-BRAF Fusion Using Pembrolizumab Followed by Trametinib: A Case Report. Yasui S; Honda T; Onishi I; Ikeda S; Miyazaki Y Cureus; 2024 Feb; 16(2):e54739. PubMed ID: 38523924 [TBL] [Abstract][Full Text] [Related]
2. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced Xue Y; Ren Y; Yan B; Li Z; Huang C Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742 [TBL] [Abstract][Full Text] [Related]
3. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib. Guo W; Liang J; Zhang D; Huang X; Lv Y Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report. Li J; Wang Q; Ge J; Tian Y; Yao W Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065 [TBL] [Abstract][Full Text] [Related]
7. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860 [TBL] [Abstract][Full Text] [Related]
8. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. Joshi M; Rice SJ; Liu X; Miller B; Belani CP PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985 [TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF Zeng Q; Deng Y; Zhang L; Wang W Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623 [TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
11. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. Dimou A; Barron G; Merrick DT; Kolfenbach J; Doebele RC BMC Cancer; 2020 Mar; 20(1):177. PubMed ID: 32131760 [TBL] [Abstract][Full Text] [Related]
12. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158 [TBL] [Abstract][Full Text] [Related]
13. Targeting Baik CS; Myall NJ; Wakelee HA Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464 [TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093 [TBL] [Abstract][Full Text] [Related]
15. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Li SD; Martial A; Schrock AB; Liu JJ Exp Hematol Oncol; 2017; 6():29. PubMed ID: 29142786 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Khunger A; Khunger M; Velcheti V Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366 [TBL] [Abstract][Full Text] [Related]
17. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631 [TBL] [Abstract][Full Text] [Related]
18. Adverse Event Management in Patients with Chalmers A; Cannon L; Akerley W Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499 [TBL] [Abstract][Full Text] [Related]